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A new design of a lentiviral shRNA vector 
with inducible co-expression of ARGONAUTE 2 
for enhancing gene silencing efficiency
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Jun Luo3, Lin Liu4 and Deming Gou1*
Abstract 
Background: RNA interference (RNAi) is a robust tool for inhibiting specific gene expression, but it is limited by 
the uncertain efficiency of siRNA or shRNA constructs. It has been shown that the overexpression of ARGONAUTE 2 
(AGO2) protein increases silencing efficiency. However, the key elements required for AGO2-mediated enhancement 
of gene silencing in lentiviral vector has not been well studied.
Results: To explore the application of AGO2-based shRNA system in mammalian cells, we designed shRNA vectors 
targeting the EGFP reporter gene and evaluated the effects of various factors on silencing efficiency including stem 
length, loop sequence, antisense location as well as the ratio between AGO2 and shRNA. We found that 19 ~ 21-bp 
stem and 6- or 9-nt loop structure in the sense-loop-antisense (S-L-AS) orientation was an optimal design in the 
AGO2-shRNA system. Then, we constructed a single lentiviral vector co-expressing shRNA and AGO2 and demon-
strated that the simultaneous expression of shRNA and AGO2 can achieve robust silencing of exogenous DsRed2 and 
endogenous ID1 and P65 genes. However, the titers of packaged lentivirus from constitutive expression of AGO2 vec-
tor were extremely low, severely limiting its broad application. For the first time, we demonstrated that the problem 
can be significantly improved by using the inducible expression of AGO2 lentiviral system.
Conclusions: We reported a novel lentiviral vector with an optimal design of shRNA and inducible AGO2 overexpres-
sion which provides a new tool for RNAi research.
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Background
Over one and a half decades after RNA inference (RNAi) 
discovery in nematodes [1], RNAi-based technology (e.g. 
siRNA and shRNA) is now widely used for gene knock-
down in basic scientific research and provides promise to 
new therapeutic strategies for a variety of diseases [2, 3]. 
With the development of siRNA or shRNA libraries, and 
high-throughput screening techniques, genome-wide 
RNAi screening is employed for broad and unbiased 
identification of genetic modifiers of various cell- or 
organism-based phenotypes [4, 5].
In principle, RNAi can be used to repress the expres-
sion of any genes. However, it is still much unknown 
about the siRNA biogenesis and action of mechanism. 
The application of RNAi technique is limited by the 
inconsistent efficiency of targeting sequences [6]. The 
existing computational approaches for siRNA selec-
tion allow the identification of potential sequences, but 
they do not ensure that each selected siRNA has suf-
ficient silencing efficiency. It has been observed that 
many designed siRNAs or shRNAs are not effective. 
On average, about 25  % of the selected siRNA/shRNA 
sequences are functional with a knockdown efficiency 
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more than 75 %. As a result, it is recommended to screen 
highly potent siRNA/shRNA sequences from at least 
four potential sites of a given mRNA [7]. Therefore, an 
approach to enhance RNAi efficiency is desired for its 
broad applications in gene-function analysis, drug-target 
discovery and validation, and developing therapeutic 
siRNA/shRNA for various diseases.
Several attempts have been made to improve RNAi effi-
cacy. For example, modifications can be made to improve 
the stability of chemically synthesized siRNA, resulting 
in enhanced siRNA inhibition efficacy [8]. For vector-
based shRNA, improvements can be achieved through 
manipulating expression strategy, using different types of 
promoters, modifying shRNA structures, and simultane-
ously expressing multiple shRNAs in a single vector [9–
13]. Another strategy was developed to enhance siRNA 
biogenesis using the small molecule, enoxacin. Impor-
tantly, this molecule has only minor effects on cellular 
gene or miRNA expression [14].
Over the last few years, a better understanding of RNAi 
mechanism facilitates the identification of key proteins 
involved in the RNAi pathway, including the members of 
the ARGONAUTE family, DICER, EXPORTIN-5 (XPO5) 
and trp  RNA-binding  attenuation  protein (TRAP) [15, 
16]. Several groups have demonstrated that co-expres-
sion of some key components with shRNAs increases the 
RNAi efficacy [6, 17–19]. For example, overexpression of 
XPO5, a factor required for nuclear export of both shR-
NAs and pre-miRNAs, enhances RNAi mediated by shR-
NAs [17]. Similarly, overexpressing AGO2 also increases 
efficiency of siRNA or shRNA-mediated gene silencing 
in vitro and in vivo [6, 19–22]. In this study, we evaluated 
key elements required for AGO2-mediated enhancement 
of gene silencing and developed a novel lentiviral shRNA 
vector with inducible co-expression of AGO2.
Results
Co‑expression of AGO2 protein strongly enhances shRNA 
silencing activities
We first examined the efficiency of two shRNA sequences 
in silencing EGPF. U6 promoter-driven shEGFP417, 
shEGFP450 or an unrelated control (shCon) vector was 
co-transfected with pENTR/CMV-EGFP and pDsRed2-
c1 plasmids into HEK293 cells. Two days after trans-
fection, shEGFP417 exhibited an ~84  % knockdown 
efficiency compared to shCon, while shEGFP450 showed 
a weak silent activity (Fig. 1a).
To test whether the increase in protein levels of some 
crucial components in RNAi machinery would facili-
tate the silencing effect, we co-transfectd AGO1, AGO2, 
Dicer or XPO5 with shRNA vector into HEK293 cells 
and examined silencing efficiency. The results showed 
that AGO2 overexpression significantly enhanced the 
silencing activities of shEGFP417 from 84  %  ±  2.1 
to 96  %  ±  1.8 and shEGFP450 from 12  %  ±  9.2 to 
70 % ± 4.4, respectively (Fig. 1b, c, d). However, overex-
pression of XPO5 showed merely a limited improvement 
of silencing activities compared to that of AGO2 (Fig. 1b, 
c). Overexpression of AGO1 and DICER did not show 
any enhancement in gene silencing.
Evidence from a large-scale study has indicated that 
miR-30a-based shRNAmiR30 vector produced a more 
effective silencing activity [23]. Therefore, we further 
examined the effects of these RNAi components on 
shRNAmiR30-based gene silencing by co-transfect-
ing pSM2c-shEGFP417miR30 vector, EGFP/DsRed2-
expressing plasmids and a vector overexpressing each 
RNAi component. Similar to the results using the 
U6-shRNA system, overexpression of AGO2 also showed 
the most significant improvement of silencing efficacy 
with the miR-30a-based shRNA vector (Fig.  1e). These 
data also suggested that AGO2 was a dominant factor 
facilitating miR-30a-based shRNA activities and likely to 
be a limiting factor for the efficient knockdown.
Next, we evaluated the effects of the ratio between 
shRNA and AGO2 overexpression vectors on silenc-
ing efficiency. We co-transfected 100  ng of ineffective 
pENTR/U6-shEGFP450 vector and various amounts of 
pIRESneo-FLAG/HA-AGO2 (100, 200, 400 ng) together 
with 50  ng of EGFP-expressing and 50  ng of DsRed2-
expressing vectors, obtaining a shEGFP450 to AGO2 
mass ratio of 1:1, 1:2 and 1:4. Normalized to the nega-
tive control, which was made by removing AGO2 insert 
from the original pIRESneo-FLAG/HA-AGO2 vector, 
the silencing efficiencies of shEGFP450 with various 
amounts of AGO2 were all significantly increased due to 
the co-transfection of AGO2 vector. Although the silenc-
ing activities can be further improved with an increasing 
amount of AGO2 (1:2 and 1:4 of shEGFP450 to AGO2), 
the minimal amount of AGO2 plasmid at the mass ratio 
of 1:1 was sufficient to improve the silencing activity 
significantly (Fig.  2). It also implied that co-expression 
of AGO2 and shRNA in a single vector might achieve a 
prominent effect of silencing.
Effects of stem length, loop size, and antisense strand 
location on the efficacy of AGO2‑shRNA
We evaluated the effects of AGO2 on the silencing effi-
ciency of different shRNA structures. We designed a set 
of hairpins with different stem lengths, ranging from 
18–22  bp (Fig.  3a). Compared to an unrelated control 
vector (shCon), the shRNAs alone with stem lengths 
between 19 and 22 bp showed 76, 83, 80 and 68 % inhibi-
tion (Fig. 3b). However, the shRNA with an 18 bp stem 
length showed no notable inhibitory activity. Overex-
pressing AGO2 significantly improved the silencing 
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activities of all the shEGFP417 with different stem lengths 
(Fig.  3b). Consistent with the traditional shRNA design 
[24], the hairpins ranging from 19–21 bp in stem length 
produced better knockdown activities in our new design 
of AGO2/shRNA co-overexpression system.
To further improve the AGO2/shRNA system, we 
constructed several variants of shEGFP417 with differ-
ent loop sizes (Fig. 3c). As shown in Fig. 3d, 19 bp stem 
length of shEGFP417 with 4-nt (TTCG), 6-nt (CTCGAG) 
or 9-nt (TTCAAGAGA) loop sequences exhibited differ-
ent knockdown efficiency. We observed that the silencing 
efficiency of the shEGFP417 with 6-nt CTCGAG loop 
was comparable to that with the 9-nt TTCAAGAGA 
loop (>75  %). However, shEGFP417 with 4-nt loop 
sequence showed much less inhibition (~30  %). When 
AGO2 protein was co-expressed, the silencing efficiency 
of shEGFP417 with 4-, 6- or 9-nt loop were all improved 
dramatically.
According to the previous reports, silencing efficiency 
of shRNA was also influenced by the position of anti-
sense sequences [25, 26]. We therefore constructed 
19  bp stem length of shEGFP417 with three different 
Fig. 1 Effects of AGO1, AGO2, DICER or XPO5 overexpression on gene silencing. a Comparison of the silencing activities of two shRNAs against 
EGFP. HEK293 cells were co-transfected with pENTR/CMV-EGFP, pDsRed2-c1 and U6 promoter-driven shEGFP450, shEGFP417 or an unrelated 
shCon. Two days after transfection, the cells were then collected for flow cytometry analysis to evaluate EGFP knockdown efficiency by determining 
green to red (G/R) fluorescence intensity ratio; b, c effects of AGO1, AGO2, Dicer or XPO5 overexpression on the silencing of EGFP with shEGFP417 
or shEGFP450. HEK293 cells were co-transfected with shRNA plasmid (shEGFP450, shEGFP417 or shCon), pENTR/CMV-EGFP, pDsRed2-c1 and 
plasmid expressing AGO1, AGO2, Dicer, XPO5 or empty control vector. Two days after transfection, G/R fluorescence intensity ratio was analyzed by 
flow cytometry and normalized to the shCon/control group; d representative images from the cells 2 days after transfection of pENTR/CMV-EGFP, 
pDsRed2-c1 and shGFP450 plasmids in the presence of AGO1, AGO2, Dicer, XPO5 or empty control vector; e G/R fluorescence intensity ratio meas-
ured from the cells transfected with shRNAmiR30a-based shEGFP417 (shEGFP417-miR30a) and the plasmid expressing AGO1, AGO2, Dicer, XPO5 or 
empty vector control. The results shown are mean ± standard deviation (SD) from three independent experiments. *P < 0. 05, ***P < 0.001
Page 4 of 12He et al. Cell Biosci  (2015) 5:67 
sizes of loop at the orientation of antisense-loop-sense 
(AS-L-S) or sense-loop-antisense (S-L-AS) structures 
(Fig.  3c). When vectors expressing these shRNAs, 
EGFP/DsRed2 and AGO2 were co-transfected into 
HEK293 cells, we found that the silencing activities of 
shEGFP with 6- or 9-nt loop sequences in AS-L-S ori-
entation were lower than the corresponding shRNA in 
S-L-AS orientation (Fig.  3d). Co-expression of AGO2 
protein improved the silencing activities of AS-L-S shR-
NAs, but the efficiency was still lower than the respec-
tive AGO2-co-expressed traditional S-L-AS shRNA 
constructs. Overall, the results provide us a general 
guideline that 19–21-bp stem and 6- or 9-nt loop struc-
ture in the S-L-AS orientation should be used for the 
new AGO2-shRNA system.
Effects of a single lentiviral vector co‑expressing shRNA 
and AGO2 on silencing efficiency
The aim of the studies in this section is to create a len-
tiviral vector that allows co-expression of shRNA and 
AGO2 using a single vector for a convenient shRNA 
cloning. To evaluate the silencing efficiency of a single 
vector co-expressing shRNA and AGO2, we applied the 
Dharmacon on-line siRNA design software to DsRed2 
coding region and randomly chose nine siRNA sequences 
(Fig. 4a). For each shRNA, a single lentiviral vector har-
boring U6-shRNA and CMV-AGO2 expression cassettes 
was constructed as shown in Fig. 4b. For comparison, the 
respective U6-shRNA alone lentiviral vectors were gen-
erated by removing the AGO2 fragments. Nine shRNA/
AGO2 or shRNA/control vectors were co-transfected 
Fig. 2 Dose-dependent analysis of AGO2 overexpression on RNAi efficiency. a Dose-dependent effects of AGO2 overexpression on EGFP silencing. 
HEK293 cells were co-transfected with pENTR/CMV-EGFP, pDsRed2-c1, shEGFP450 and different amount of AGO2 overexpression vector or the 
control vector without AGO2 insert. Representative images were shown from the cells 2 days after transfection; b the effect of AGO2 overexpression 
on EGFP silencing activities was quantified by analyzing G/R fluorescence intensity ratio. The results shown are mean ± SD from four independent 
experiments. ***P < 0.001 vs. control
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with EGFP/DsRed2 plasmids into HEK293 cells cultured 
in 24-well plates. Forty-eight hous after transfection, 
fluorescence intensity was visualized by fluorescence 
microscopy, followed by flow cytometry analysis. With-
out AGO2, shDsRed2-276, -403, -534 and -350 achieved 
over 70  % knockdown while shDsRed2-23, -130, -343 
and -623 had moderate silencing activities (41–63  %); 
the shDsRed2-203 displayed the lowest silencing activ-
ity (11  %) (Fig.  4c). In contrast, with the shRNA/AGO2 
vectors, all shDsRed2 exhibited significant knockdown 
of DsRed2 protein and the least effective shDsRed2-203 
achieved an 88 % suppression of DsRed2 (Fig. 4c). These 
results indicate that RNAi activity is at least in part 
dependent on the co-expression of AGO2 protein in cells.
Given the effectiveness of AGO2 in enhancing RNAi, 
we tested the shRNA/AGO2 vector for suppress-
ing endogenous proteins. Inhibitor of Differentiation 
(ID1), an important helix-loop-helix (HLH) transcrip-
tion factor involved in the proliferation and progression 
of many cancer types, was selected for this purpose. 
We selected six siRNA sequences targeting human 
ID1 coding region at different positions (Fig.  5a) and 
constructed lentiviral vectors expressing each shRNA 
with or without AGO2 co-expression. HeLa cells were 
infected with the lentivirus and the infected cells were 
selected using puromycin to assure complete infec-
tion. Without AGO2 co-expression, shID1-316, shID1-
369 and shID1-429 displayed ~70  % knockdown of 
Fig. 3 Effect of stem length, loop size, and antisense strand location of shRNA on RNAi efficiency. a Design of a set of shEGFP variants with different 
stem lengths. The stem lengths were indicated in the name of each shRNA. All the constructs were designed to target EGFP, starting at the position 
of 417 of EGPF with the stem sequence extending to the 3′ direction. The hairpin loop was the same (5′-TTCAAGAGA-3′) for all of the vectors; b 
comparison of the activities of shRNAs with different stem lengths in HEK293 cells. G/R fluorescence intensity ratio was measured from the cells 
co-transfected with pENTR/CMV-EGFP, pDsRed2-c1, shRNA vector with or without AGO2 overexpression vector. shCon/control group was used to 
normalize the silencing efficiency; c design of 19-bp hairpin stem of shEGFP417 at the orientation of Sense-Loop-Antisense (S-L-AS) or Antisense-
Loop-Sense (AS-L-S) structure with three kinds of loop sequences, L1 (4-nt, TTCG), L2, (6-nt, CTCGAG) or L3 (9-nt, TTCAAGAGA); d comparison of the 
activities of S-L-AS and AS-L-S shRNA with different loop lengths in the presence or absence of AGO2 co-expression. ShCon/control group was used 
for the normalization of EGFP silencing activities. The results shown are mean ± SD from four independent experiments. ***P < 0.001
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endogenous ID1 protein, shID1-303; shID1-403 exhib-
ited ~60  % silencing while shID1-285 suppressed only 
~30 % of ID1 compared to the shCon vector. (Fig. 5b). 
With AGO2 co-expression, all shID1 achieved over 70 % 
knockdown. However, all the shID1-AGO2 vectors had 
no effect on the expression of ID2, another member of 
ID family (Fig.  5b), indicating the specific silencing of 
shRNA-AGO2 system.
Functionally, we examined the effect of ID1 knockdown 
on cell proliferation and observed that all shID1-AGO2 
infected HeLa cells had a lower cell proliferation rate 
compared to each corresponding shID1 without AGO2 
co-expression (Fig. 5c).
P65 was selected as another target for the shRNA-
AGO2 system and three shRNAs were chosen (Fig. 5a). 
As shown in Fig.  5d, without AGO2 co-expression, 
Fig. 4 Co-expression of AGO2 enhances shRNA-mediated knockdown of DsRed2 florescence reporter. a Design of a set of shRNAs targeting 
DsRed2 coding region at different positions; b a schematic illustration of a shRNA lentiviral vector with CMV promoter-driven AGO2 (shRNA/AGO2). 
The corresponding control (shRNA/control) was generated by removing AGO2 fragment; c U6-driven shRNA with the co-expression of CMV-driven 
AGO2 or its control in the single plasmid were co-transfected with EGFP/DsReds plasmids into HEK293. Two days after transfection, R/G fluores-
cence intensity ratio was measured by flow cytometry analysis and the silencing efficiency was normalized to the shCon/control group. The results 
shown are mean ± SD from four independent experiments. ***P < 0.001
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shP65-380 and shP65-1069 exhibited a moderate silenc-
ing efficiency while shP65-1622 was less effective. How-
ever, the co-expression of AGO2 significantly improved 
the knockdown efficiency, further supporting that AGO2 
plays an essential role in shRNA-mediated gene silencing.
A shRNA lentiviral vector with inducible AGO2 expression
The virus titers from the CMV promoter-driven AGO2 
vector were extremely low (<103 pfu/ml), which sig-
nificantly limited its application. This is likely due to 
negatively impact of the package of lentivirus by the 
Fig. 5 Co-expression of AGO2 enhances shRNA-mediated knockdown of endogenous genes. a Design of a set of shRNAs targeting human ID1 or 
P65 mRNA at different regions. The number indicates the initial position of siRNA in the coding region of genes; b a lentivirus harboring U6-driven 
shID1 and CMV-driven AGO2 or its control was used to infect HeLa cells twice and selected with puromycin for 1 week. Representatives of Western 
blots using anti-ID1 or anti-ID2 antibodies were shown. β-actin was used as a loading control; c HeLa cell proliferation after silencing of ID1. The 
same number of stably selected HeLa cells expressing shRNA with or without AGO2 protein were seeded on 96-well plates at a density of 1 × 104 
cells per well. After 24 h culture, cell proliferation was determined. The results shown are mean ± SD from four independent experiments. *P < 0.05 
vs shCon, ***P < 0.001 vs shCon; d Western blot showing the knockdown of P65 in HeLa cells with a lentivirus-based shRNA with or without AGO2 
co-expression. shCon was used as a negative control. β-actin was used as a loading control
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constitutive overexpression of FLAG/HA/AGO2. To 
overcome this difficulty, we generated a new shRNA 
lentiviral vector (TAIPz-shRNA) inductively express-
ing AGO2, which consists of U6-driven shRNA, TETO6 
inducible promoter-drived FLAG/HA/AGO2 and Ubc 
promoter-drived rtTA3 transactivator (Fig. 6a). The virus 
titer packaged from the pTAIPz-shRNA was significantly 
increased over 1000 times (up to 106pfu/ml) compared 
to the constitutive overexpression of AGO2. Next, we 
analyzed the shRNA knockdown efficiencies against Fus 
and PALLD targets in the infected cells with or without 
AGO2 induction. The expression of both targets were sig-
nificantly reduced even without AGO2 induction. Simi-
lar to the results above, the silencing efficiencies of shFus 
and shPALLD were further enhanced by the induction of 
AGO2 expression in the presence of DOX (Fig. 6b). The 
successful induction of FLAG/HA/AGO2 was confirmed 
by Western blot using anti-HA antibody (Fig.  6b). The 
shRNA lentiviral vector with inducible AGO2 overexpres-
sion may serve as an additional tool for RNAi research in 
case of inhibitory shRNA sequences with low efficiency.
Discussion
RNAi-based siRNA/shRNA has been developed as a 
robust tool for the inhibition of gene expression in vitro 
and in vivo. Nevertheless, the uncertainty of RNAi silenc-
ing efficiency is still a restriction of its application. As a 
key component of the RNA-induced silencing complex 
(RISC), AGO2 is responsible for the endonuclease cleav-
age of target mRNAs [20]. The process of RNAi cannot 
be accomplished without AGO2. Several studies have 
shown that the overexpression of AGO2 significantly 
improves shRNA-mediated gene silencing. Diederichs 
et al. co-transfected HEK293 cells with vectors express-
ing AGO2 and shEGFP and showed that AGO2 overex-
pression significantly enhanced the silencing efficiency 
of shEGFP [6]. Chen et al. found co-expression of AGO2 
enhanced shRNA-induced RNAi in Xenopus CNS Neu-
rons in  vivo [19]. Similarly, Grimm et  al. demonstrated 
that AGO2 obviously enhanced the inhibition efficiency 
and extended the inhibition time of shRNAs in mice. It 
also reduced the liver toxicity caused by shRNA [18]. 
Recently, the distinctive AGO2 property has been fur-
ther exploited by constructing an Adeno-associated viral 
vector co-expressing AGO2 and shRNA [22]. They also 
showed that AGO2-overexpressing cell lines generated 
through lentiviral transduction yielded a better siRNA 
inhibition outcome and improved RNAi phenotypes. But 
they did not demonstrate the successful application of a 
single lentiviral vector co-expressing shRNA and AGO2.
Fig. 6 Enhancement of shRNA efficiency achieved by DOX inducible AGO2 overexpression lentiviral vector. a A schematic illustration of pTAIPz-
shRNA lentiviral vector co-expressing U6-driven shRNA and inducible AGO2 under control of the tetracycline-inducible TETO6 promoter; b com-
parison of two target genes knockdown in A549 cells infected with lentivirus expressing shRNA with or without AGO2 induction. β-actin served as 
the loading control
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In this study, we found that the overexpression of 
AGO2 strongly increased silencing efficiency of shRNAs. 
This effect was observed not only in U6-driven tradi-
tional shRNAs, but also in miR-30a-based shRNAmir30. 
In contrast, overexpression of AGO1, DICER or XPO5 
did not exhibit significant improvement of RNAi activi-
ties even though they are essential in transporting or pro-
cessing precursor dsRNAs.
As the knockdown efficiency of shRNAs is affected 
by the length of stem, the loop sequences and the loca-
tion of antisense strand in shRNA structure [7, 27], we 
evaluated the effects of these factors in the new designed 
AGO2/shRNA co-expression system. Similar to tradi-
tional shRNAs, a hairpin ranging from 19–21  bp with 
6–9 nt loop produces a better knockdown activity in the 
AGO2/shRNA system. In contrast to the previous report 
showing that the artificially synthesized AS-L-S shRNA 
outshined S-L-AS shRNA in gene silencing [28], our 
data indicate that S-L-AS shRNA was much more effi-
cient than AS-L-S shRNA in gene silencing. This is also 
the case when the shRNA structures were co-expressed 
with AGO2, even though silencing efficiencies of both 
shRNA structures were dramatically increased by the 
overexpression of AGO2. The detailed mechanism of the 
different inhibition efficiencies driven by these two types 
of shRNA remains unclear. But, the discrepancy could be 
due to different genes that are targeted.
Based on the evaluation of shRNAs targeting either 
exogenous DsRed2 or endogenous ID1 and P65 genes, we 
demonstrate that the co-expression of shRNA and AGO2 
in a single vector achieved a robust gene silencing out-
come. Vector-based shRNA has its limitation due to the 
low transfection efficiency in many types of cells, poor 
integration ability, and insufficient expression level. Len-
tiviral vectors are a promising tool for both in vivo and 
ex vivo gene therapy as well as their extensively applica-
tion in basic biomedical research because of their ability 
to incorporate into genomic DNA with high efficiency, 
especially in cells that are not actively dividing.  The 
approach of lentivirus-based shRNA/AGO2 makes it 
possible in improving the shRNA-mediated silencing of 
the target mRNA, which provides a promising tool for 
RNAi application. Similar strategy should be also useful 
for miRNA overexpression in mammalian cells.
When we packaged lentivirus in 293T cells using a len-
tiviral vector with U6-driven shRNA and CMV-driven 
AGO2 expression cassettes, we observed that the lenti-
virus titer was extremely low. Initially, we thought that 
the low titer might be caused by the over-limited size of 
AGO2 insert in the lentiviral vector. However, when we 
removed the PGK-Puro expression cassette, we did not 
observe any improvements in virus titer. This suggests 
that the low virus titer is probably due to constitutive 
expression of AGO2. Indeed, the virus titer from induc-
ible AGO2-shRNA vector was increased by over 1000 
fold. This new inducible AGO2-shRNA lentiviral expres-
sion vector contains the TETO6-mini promoter-driven 
AGO2, Ubc promoter-driven rtTA3 and U6-shRNA 
expression cassette. When AGO2 was induced by the 
addition of Dox, the RNAi efficiency was significantly 
improved. The modified strategy of constitutive expres-
sion of shRNA and inducible expression of AGO2 in a 
single lentiviral-vector has advantages of a low toxicity 
and prolonged efficacy.
Conclusions
We reported a novel lentiviral vector with an optimal 
design of shRNA and inducible AGO2 overexpression 
which has a robust silencing of exogenous and endoge-
nous targets in mammalian cells and provides a powerful 




AGO2, pDEST-myc-Dicer, and pkmyc-XPO5, overex-
pressing human AGO1, AGO2, DICER or EXPORTIN-5 
(XPO5) were purchased from Addgene. pIRESneo-
FLAG/HA-Control generated from pIRESneo-FLAG/
HA-AGO2 by removing the AGO2 sequence was 
used as a negative control for AGO2 experiment. The 
codon-optimized human AGO2 with FLAG/HA tags in 
pCAhU6 vector was kindly provided by Dr. Dirk Grimm 
(University of Heidelberg). pDsRed2-c1 vector expressing 
red florescence protein was purchased from Clontech. 
pENTR/CMV-EGFP vector expressing enhanced green 
florescence protein (EGFP) was generated as previously 
described [10].
Human U6 promoter-driven shRNAs were constructed 
using linearized  BLOCK-iT™ U6 RNAi Entry Vector 
(Invitrogen). Two siRNA sequences with different silenc-
ing activities against EGFP coding region at position of 
417-437 (5′-GCA CAA GCT GGA GTA CAA CTA-
3′) and 450-470 (5′-CGT CTA TAT CAT GGC CGA 
CAA-3′) were selected for constructing EGFP silencing 
vectors, named pENTR/U6-shEGFP417 and pENTR/
U6-shEGFP450. pSM2c-shEGFP417miR30 (Openbiosys-
tem) was a miR-30-based shEGFP417 vector targeting 
EGFP at the same position of 417-437.
To construct lentiviral vectors co-expressing shR-
NAs and AGO2, the pLVX-puro vector (Clontech) was 
selected as a backbone plasmid. Since there are two 
BsmBI sites located in PGK promoter and puromycin 
resistant selection gene in the pLVX-puro vector, we 
removed both BsmBI sites via mutagenesis using overlap 
PCR strategy. The BsmBI site in the PGK promoter was 
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changed to CGCCTC, which did not affect the promoter 
activity (data not shown). The BsmBI site in the puromy-
cin resistant selection gene was changed to CGTGTC 
without affecting the encoded amino acid. The modified 
pLVX-puro was then digested with ClaI and XbaI and 
used for cloning U6 and CMV-AGO2 expression cas-
settes with Gibson Assembly kit (New England Biolab). 
Briefly, U6 promoter was PCR-amplified with the for-
ward primer (5′-GCA GAG ATC CAG TTT ATC GAA 
CAA TCG ATA AGG TCG GGC AGG A-3′) and reverse 
primer (5′-CAA TGT CAA CGC GTA AAA AAG AGA 
CGC GTC TCA CGG TGT TTC GTC CTT TC-3′). 
Two BsmBI sites (underlined) in the reverse primer were 
included for cloning shRNA inserts. CMV-FLAG/HA/
AGO2 fragment was amplified with the forward primer 
(5′-TTT TTT ACG CGT TGA CAT TGA TTA TTG 
ACT AGT TAT TAA TAG-3′) and reverse primer (5′-
CTA CCC GGT AGA ATT ATA TAG CGA TCC ACT 
GAA TTC-3′) using a codon-optimized AGO2 vector 
of pCAnU6 as a template. We inserted a ccdB fragment 
with corresponding BsmBI site into the assembled vec-
tor, named pLVX/U6-ccdB-CMV-AGO2, which can 
be further digested by BsmBI, leaving five overhangs of 
5′-CGGT and 5′-TTTT for the ligation of an annealed 
shRNA insert with 5′ overhangs of 5′-ACCG and 
5′-AAAA.
To construct an inducible AGO2 lentiviral vector, the 
TurboRFP fragment in pTRIPz control vector (Open-
biosystems) was first digested with AgeI, blunt-end with 
Klenows in the presence of dNTP, and then digested 
with EcoRI. The insert of AGO2 with FLAG/HA tag at 
the N-terminus was released from the pCAhU6 vector 
by Acc65I digestion, blunt-end with Klenows, and then 
digested with EcoR1. The new construct of pTAIPz con-
sists of 6 repeats of a 19  bp tet operator sequence, fol-
lowed by a minimal CMV promoter (miniP) and FLAG/
HA/AGO2 insert. The co-expression rtTA3 transacti-
vator and IRES-based puromycin is controlled by the 
human ubiquitin C (Ubc) promoter.
To generate a single lentiviral vector co-expressing 
shRNA and inducible AGO2, the U6-shRNA expression 
cassette released from pLVX-U6-shRNA-CMV-AGO2 
was subcloned into the pTAIPz vector through EcoRI-
MluI sites, resulting in a pTAIPz-shRNA construct.
Mammalian cell culture and fluorescence reporter assays
HEK293, HeLa, and A549 cells were obtained from 
American Type Culture Collection (ATCC) and were 
grown in DMEM medium with 10 % fetal bovine serum 
(FBS). The fluorescence reporter assays were performed 
in 24-well plates. In brief, cells were seeded at a density 
of 6 × 104 cells per well. After overnight incubation, the 
cells were co-transfected with different combinations 
of plasmids using linear polyethylenimine (PEI) trans-
fection reagent. Six h after transfection, the cells were 
changed to fresh DMEM medium containing 10  % FBS 
and incubated for additional 48  h. The fluorescence of 
cells were first observed and photographed under an 
inverted fluorescence microscope, then trypsinized, and 
collected for flow cytometry analysis. The averaged green 
to red (G/R) or red to green (R/G) fluorescence ratio was 
used as an index for RNAi efficiency of EGFP or DsRed2 
knockdown.
Lentivirus package and transduction
Lentiviral particles were packaged in 293T cells by trans-
fection of three individual plasmids at a ratio of 3:1:3: (1) 
psPAX2 encoding HIV Gag-Pol (Addgene, 12260), (2) 
pVSVg (Addgene, 8454) encoding VSV-G glycoprotein, 
and (3) a lentiviral vector. Briefly, 293T cells were seeded 
on 10 cm culture dishes at a density of 4 × 106 cells per 
dish. After 24  h incubation, the cells were transfected 
with lentiviral vector (6.9  µg) and packing plasmids 
(17.1 µg) using PEI reagents. Cell-free supernatants were 
harvested 48 and 72  h after transfection and used for 
subsequent cell infection in the presence of 8 ng/ml poly-
brene. The infected cells were selected by supplementing 
culture medium with 1–2  µg/ml puromycin after 48  h 
infection.
Cell proliferation assay
A lentivirus expressing shRNA against ID1 or an un-
related control shRNA with or without AGO2 co-expres-
sion were used to infect HeLa cells in the presence of 
polybrene. After 48  h infection, the infected cells were 
selected by supplementing culture medium with 1.5 µg/
ml puromycin. Cell proliferation was then determined 
using the CellTiter 96 Aqueous One Solution prolifera-
tion assay (Promega).
Western blot analysis
Cells were lysed with ice-cold RIPA buffer (50 mM Tris–
HCl, pH 7.5; 150 mM NaCl; 1 % NP-40; 0.25 % sodium 
deoxycholate, 1  mM EDTA), supplemented with a pro-
tease inhibitor cocktail (Roche). Protein concentra-
tion was determined using Bradford protein assay kit 
(Bio-Rad). Equal amounts of extracts were then electro-
phoresed on SDS–polyacrylamide gel and electro-blotted 
to nitrocellulose filter membranes (Millipore). Mem-
branes were immersed in blocking buffer (5 % degreased 
milk powder) for 1  h and incubated with primary anti-
bodies. The primary antibodies used are as follows: rab-
bit monoclonal anti-ID1, -ID2 (Cat #MA201, #MA229, 
CalBioreagents, San Mateo, CA, USA; 1:1000 dilutions); 
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rabbit polyclonal anti-P65 (Cat #SC-372, Santa Cruz, 
Santa Cruz, CA, USA, 1:800 dilutions), rabbit poly-
clonal anti-Fus, anti-PALLD, anti-beta-actin and anti-
HA (Proteintech Group, 1:2000 dilutions). After rinsing, 
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody at dilutions of 1:10,000 
for 1 h at room temperature. Immunoreactive bands were 
detected by exposing to X-ray film.
Statistical analysis
All data shown are mean values of at least four experi-
ments, each performed in triplicate, with standard devia-
tion (SD). Statistically significant differences between 
groups were evaluated using the SPSS software. One 
asterisk, double asterisk, and three asterisks represent 
a significant difference between experimental pairs of 
p < 0.05, 0.01, and 0.001, respectively.
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